Thrivent Financial for Lutherans Sells 1,424 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Thrivent Financial for Lutherans lessened its position in NeoGenomics, Inc. (NASDAQ:NEO) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 99,217 shares of the medical research company’s stock after selling 1,424 shares during the period. Thrivent Financial for Lutherans owned 0.08% of NeoGenomics worth $1,635,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new stake in NeoGenomics in the fourth quarter worth $26,000. Versant Capital Management Inc lifted its position in shares of NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,142 shares during the period. Quarry LP purchased a new stake in shares of NeoGenomics in the 3rd quarter worth about $40,000. Smartleaf Asset Management LLC boosted its stake in shares of NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 2,787 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of NeoGenomics by 33.2% during the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock valued at $73,000 after buying an additional 1,103 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Up 1.5 %

NASDAQ:NEO opened at $9.62 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The firm has a market cap of $1.24 billion, a P/E ratio of -15.52 and a beta of 1.28. NeoGenomics, Inc. has a fifty-two week low of $8.98 and a fifty-two week high of $19.12. The firm has a 50-day simple moving average of $11.92 and a two-hundred day simple moving average of $14.34.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. Analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on NEO. Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Needham & Company LLC decreased their price objective on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Piper Sandler reduced their target price on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Bank of America decreased their price target on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. Finally, Jefferies Financial Group started coverage on shares of NeoGenomics in a research note on Tuesday, December 10th. They set a “buy” rating and a $22.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.